Association of Low and Intermediate Combined Positive Scores With Outcomes of Treatment With Pembrolizumab in Patients With Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma: Secondary Analysis of Keynote 048.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 35679031.
- Also identified by DOI 10.1001/jamaoncol.2022.1846 and PMC identifier 9185518.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This secondary analysis of the Keynote 048 trial examines treatment with pembrolizumab in patients with recurrent and metastatic head and neck squamous cell carcinoma.
Medical subject headings
- Antibodies, Monoclonal, Humanized
- Head and Neck Neoplasms